RS17

RS17 is an anti-tumor peptide designed to bind specifically to the CD47 molecule and block the interaction between CD47 and its ligand, SIRPα, on the surface membrane of macrophages. The main regulatory mechanism of RS17 is to prevent CD47 from transmitting selective phagocytosis signals to SIRPα by binding to CD47, so that macrophages do not recognize tumor cells as their own tissue, but phagocytose them as foreign substances, thereby inhibiting immune escape of tumor cells. RS17 can be used to study the mechanism of anti-tumor response and immune escape[1].

Product Specifications

CAS Number

[2415545-08-1]

UNSPSC

12352209

Target

CD47; Interleukin Related

Type

Peptides

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/rs17.html

Purity

99.82

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(O)=O)C(NCC(NCC(N[C@@H](CC2=CNC3=CC=CC=C23)C(N[C@@H](CO)C(N[C@@H](CC4=CNC=N4)C(N[C@@H](CC5=CNC6=CC=CC=C56)C(N[C@@H](CO)C(N7[C@@H](CCC7)C(N[C@@H](CC8=CNC9=CC=CC=C89)C(N[C@@H](CO)C(N[C@@H](CO)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCNC(N)=N)N